The current commercialization of Nurtec ODT in the U.S. is focused on its use for the acute treatment of migraine with or without aura in adults, and the preventive treatment of episodic migraine in adults [1].
What is Nurtec ODT's approved indication for migraine?
Nurtec ODT is approved for the acute treatment of migraine with or without aura in adults [1]. This means it can be used to stop a migraine attack once it has started. It is also approved for the preventive treatment of episodic migraine in adults, which involves reducing the frequency of migraine attacks [1].
When does Nurtec ODT's patent exclusivity end?
Patent exclusivity for Nurtec ODT is a complex landscape. The primary patent for the composition of matter, U.S. Patent No. 8,470,809, is listed with an expiration date of March 13, 2029 [2]. However, other patents related to its formulation and methods of use may have different expiration dates [2]. DrugPatentWatch.com tracks these patents and their expiration timelines [2].
What is the commercial outlook for Nurtec ODT approaching patent expiry?
As patent exclusivity approaches, the market often anticipates the potential for generic or biosimilar competition, depending on the drug class. For small molecule drugs like Nurtec ODT, this typically involves generic versions. The commercial strategy of the innovator company often includes efforts to extend market exclusivity through various means, such as new formulations or additional patent filings [2].
Who manufactures Nurtec ODT?
Nurtec ODT is manufactured by Biohaven Pharmaceuticals [1]. In 2022, Pfizer acquired Biohaven Pharmaceuticals, which included Nurtec ODT [3].
How does Nurtec ODT work for migraine treatment?
Nurtec ODT contains the active ingredient rimegepant, which is a calcitonin gene-related peptide (CGRP) receptor antagonist [1]. By blocking the action of CGRP, a molecule that is thought to play a role in migraine, rimegepant helps to alleviate migraine symptoms [1].
What are the key differences between acute and preventive migraine treatments?
Acute treatments, like Nurtec ODT when used for acute attacks, are designed to stop a migraine once it has begun. Preventive treatments, such as Nurtec ODT when used for prevention, aim to reduce the frequency and severity of migraine attacks over time [1].
What is the typical pricing and insurance coverage for Nurtec ODT?
Pricing and insurance coverage for prescription medications can vary significantly based on individual insurance plans, pharmacy, and geographic location. Patients are typically advised to check with their insurance provider and local pharmacy for the most accurate information regarding co-pays and prescription costs. Patient assistance programs may also be available [1].
What are the potential competitors to Nurtec ODT?
The migraine market includes other CGRP inhibitors, both oral and injectable, as well as other classes of migraine medications. Competitors for acute treatment might include triptans and other CGRP antagonists, while preventive treatments could include other CGRP therapies or older classes of preventive medications [4].
What clinical data supports Nurtec ODT's efficacy?
Clinical trials have demonstrated the efficacy of Nurtec ODT in both the acute and preventive treatment of migraine. Studies have shown statistically significant reductions in monthly migraine days for patients using it for prevention and rapid pain relief for acute attacks [1].
What are patient concerns regarding Nurtec ODT?
Patient concerns typically revolve around efficacy, side effects, cost, and insurance coverage. Like all medications, Nurtec ODT has potential side effects, which should be discussed with a healthcare provider [1].
Sources:
[1] https://www.nurtec.com/
[2] https://www.drugpatentwatch.com/
[3] https://www.pfizer.com/news/press-release/press-release-detail/pfizer-completes-acquisition-biohaven-pharmaceutical-holding
[4] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8752657/